Anon
Guest
Anon
Guest
It looks like GSK is in the process of initiating restructuring on their end. The CMO is leaving, it is her last day today, there is talk of reshaping the clinical development divisions and cutting jobs in the upcoming months. I work in discovery so I don't get to know much of what is happening in the field but after the last round of layoffs it seems like they are convinced that the way to offset lack of a pipeline is by slashing jobs. In an era where making theraflu keurig pods is now lauded as innovation, one has to question if anybody knows what they are talking about. Here are my thoughts
1. GSK will cut its job force by a significant number in the next month or so
2. They will restructure clinical development and try to move people with highly specialized expertise in one area to "area agnostic" flexibility (this is already in the works)
3. Bonus payout will be affected
4. There will be increasing push to consolidate divisions into shared upper level management. You will see people who were responsible for one section/division take over the responsibility of others ostensibly to increase "accountability" but more practically to thin the work force
5. There will be an exodus like movement out of GSK after the March bonus payout.
Thoughts?
1. GSK will cut its job force by a significant number in the next month or so
2. They will restructure clinical development and try to move people with highly specialized expertise in one area to "area agnostic" flexibility (this is already in the works)
3. Bonus payout will be affected
4. There will be increasing push to consolidate divisions into shared upper level management. You will see people who were responsible for one section/division take over the responsibility of others ostensibly to increase "accountability" but more practically to thin the work force
5. There will be an exodus like movement out of GSK after the March bonus payout.
Thoughts?